|
| |
Investors
| On September 1, 2016, the
S.E.C. Qualified
BioSculpture Technology's Tier 2 Regulation A Offering to
enable development and clinical testing of our patented endoscopic treatment
of obesity, metabolic syndrome, and type 2 diabetes
mellitus. Issuer: BioSculpture Technology, Inc.; CUSIP
Number: 09074G 106; ISIN NUMBER: US09074G1067; Issue
Description: COM. This Regulation A public offering terminated on
August 31, 2017. |
|
|
Please note this Regulation A Public
Offering terminated on August 31, 2017 and links are provided for
historical purposes only. |
Company Profile
Innovative Solutions Based on ScienceTM
BioSculpture Technology, Inc. (“BST”) is a
commercial-stage medical device manufacturer of liposuction surgical
instruments for surgeons. It offers the FDA-cleared Twin
Cannula Assisted Liposuction ("TCAL") Airbrush®
Liposculptor II, Intellimotion®
controllers, Airbrush® cannula
sets, and
multicore connectors. The company also provides warranty repairs,
physician referrals, as well as offers
license options. It serves customers through a network of manufacturer
representatives. The company was founded in 2001, incorporated
in Delaware, and is based in West Palm Beach, Florida.
BST is developing a patented
minimally invasive method and device for the endoscopic removal of
visceral or “belly” fat, Endoscopic Visceral Lipectomy
or "EVL" as a new treatment of obesity, metabolic syndrome and
type 2 diabetes mellitus. Three U.S. patents have been allowed on both the
method and device and numerous others are pending. BST filed its Form 1-A
with the S.E.C. to fund EVL development and commercialization and initiate
becoming a public company. Bringing this highly disruptive EVL technology to market is BST's
highest priority.
BST
will convert production to a next generation version of its pneumatic TCAL system, the Airbush®
Liposculptor IIE, a sleeker electrical wand. The Company
also is developing a single cannula Power Assisted Liposuction
("PAL") device, the Airbrush®
Liposculptor III, the next generation of a tissue aspiration
technology our Founder also invented but successfully licensed to UAM,
NuMed, Byron Medical, and Mentor.
|
|
|
With the exception of the above
overview and announcements that appear on this page as they are of particular interest to
investors, this website is devoted to products that are already approved for
sale and in production. You may follow activities of our Research
and Development Division, particularly in regard to our progress with Endoscopic
Visceral Lipectomy or "EVL" at www.evl.technology.
This
page is purposed to provide present and future investors with information regarding the
company's S.E.C. filings, shareholder meetings, financial reporting, material
events, progress, and other announcements. We plan to hold regularly scheduled GoToMeeting
webinars to provide C.E.O. reports on a regular basis and facilitate attendance by our shareholders
to keep them updated as to Corporate events, announcements and activities.
Please check back here at regular intervals for advance postings of their dates
and web links.
Below are the the three new products, all of
which have been successfully prototyped, but none of which have yet been
submitted for regulatory clearance, which this offering will permit the Company
to finish developing and bring to market.
|
| Robert L. Cucin, MD JD |
President, CEO, Chairman |
| Deborah Salerno |
CFO, Director |
| Julia Cucin |
Secretary, Director |
| Jonas Gayer, CPA |
Treasurer, Director |
| Peter Ciriscioli, PhD |
Director, Consultant Engineer |
|
Downloads and Web Links:
 | On September 1, 2016, the S.E.C. Qualified
BioSculpture Technology's Tier 2 Regulation A Offering to
enable development and clinical testing of our patented endoscopic treatment
of obesity, metabolic syndrome, and type 2 diabetes
mellitus. Although this Regulation A Public Offering
terminated on August 31, 2017, links to it are provided below for historical
purposes.
|
Recent Interviews of CEO, Robert L. Cucin, M.D.:
| CEO Clips |
|
Lemonlight |
|
CEO
Money
|
 |
|
 |
|
 |
| Stock News Now |
|
Tasty Trade |
|
I Heart Radio |
 |
|
 |
|
 |
Video Presentations:
|
Endoscopic
Visceral Lipectomy for Obesity and Type 2 Diabetes
|
|
Investor
Highlights
August
1,
2017 |
|
Endoscopic
Visceral Lipectomy
Medical
Video
|
 |
|
 |
|
 |
|
Investor
Highlights
January 16,
2017 |
|
Investor
Highlights
September 10,
2016 |
|
Narrated Investor
Presentation (full)
July 6,
2016
|
|
|
|
|
 |
|
 |
|
 |
Older Video Presentations:
Further Information for Accredited Investors:
|
 |
Accredited Investors,
as defined by §230.501, those that meet the
criteria summarized below, may invest in private securities not available to the
general public and generally reserved for Venture Funds. Accredited Investors
must buy those private securities for investment only and not for resale, and such securities are
restricted. However
Accredited Investors are exempt from the 10% net worth or 10% income limitation
for their investment in a Tier 2 Regulation Offering.
Accredited Investors known to us who have been granted access may
login to view private
investment opportunities when they are available. Please note our
mezzanine bond offering is now closed.
Natural persons
who meet any of these criteria are considered Accredited Investors:
| earn an individual income of more than $200,000 per year, or a joint
income of $300,000, in each of the last two years and expect to reasonably
maintain the same level of income; |
| have a net worth exceeding $1 million, either individually or jointly with
his or her spouse excluding the value of their primary residence taking into
account any debt on that is in excess of fair market value; |
| directors, executives or general partners of the issuer. |
These entities may also meet the definition of Accredited Investors:
| a bank, insurance company, registered investment company, business
development company, or small business investment company; |
| an employee benefit plan; |
| a charitable organization, corporation or partnership with assets
exceeding $5 million; |
| a business in which all the equity owners are Accredited Investors; |
| a trust with assets of at least $5 million not formed to acquire the
securities offered and whose purchases are directed by sophisticated
person |
Accredited Investors unknown to us may document their status quickly and confidentially
at with one of the numerous online services now available such as www.accredify.com
or www.verifyinvestor.com, and then contact
us for access.
| |
|
